News
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
The pharmaceutical firm Novo Nordisk is pursuing a multipronged strategy to regain market share that it has lost to Eli Lilly ...
A decision is expected in the fourth quarter of 2025.
Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...
Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...
Novo Nordisk is expanding access to its GLP-1 drug Wegovy via telehealth, partnering with Hims and Hers, Ro, and LifeMD.
CVS’s stock surges toward a one-year high after profit and revenue beat expectations, amid strength in the pharmacy business, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results